Stéphane Jouneau,1 Alain Lescoat,2 Bruno Crestani,3 Gabriela Riemekasten,4 Yasuhiro Kondoh,5 Vanessa Smith,6 Nina M Patel,7 John T Huggins,8 Christian Stock,9 Martina Gahlemann,10 Margarida Alves,11 Christopher P Denton12 on behalf of the SENSCIS trial investigators
1Department of Respiratory Medicine, Competences Centre for Rare Pulmonary Diseases, CHU Rennes, univ Rennes, Rennes, France; 2Internal Medicine, CHU South Hospital, Rennes, France; 3Hôpital Bichat, Pneumologie, Paris, France; 4University Hospital Charité, Rheumatology and Clinical Immunology, Berlin, and University Hospital Schleswig-Holstein, Rheumatology, Lübeck, Germany; 5Department of Respiratory Medicine and Allergy, Tosei General Hospital, Japan; 6Department of Rheumatology, Ghent University Hospital, Ghent, Belgium; Department of Internal Medicine, Ghent University, Ghent, Belgium; 7Division of Pulmonary, Allergy, and Critical Care Medicine, Columbia University College of Physicians and Surgeons/New York-Presbyterian Hospital, New York, NY, USA; 8Medical University of South Carolina, Charleston, South Carolina, USA; 9Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany; 10Boehringer Ingelheim (Schweiz) GmbH, Basel, Switzerland; 11Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany; 12University College London Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, London, UK
Introduction
- SSc is commonly associated with gastrointestinal complications, which increase the risk of malabsorption and underweight.1
- In the SENSCIS trial in subjects with SSc-ILD, nintedanib reduced the rate of decline in forced vital capacity (FVC) (mL/year) over 52 weeks by 44% compared with placebo, with an adverse event profile characterized mainly by gastrointestinal events.2